Judy Atkins is currently serving as Vice President of Quality and Compliance at TARGET PharmaSolutions.
Judy Atkins received her BS,MS, Doctorate of Pharmacy, and Pharmacy degree from the University of North Carolina- Chapel Hill.
Jason Fox is currently serving as Vice President of Technology at TARGET PharmaSolutions.
Jason has over 15 years’ experience in software engineering and architecture, including stints at NASA’s Jet Propulsion Laboratory and SAS. Jason is an expert in building high performing, highly available software systems for a wide array of industries. Whether it is mission support software for robotic exploration of Mars, or scalable frameworks for high-end analytics, Jason brings his methodical approach and deep understanding of computer systems to solving difficult problems.
Jason received his Master’s degree in Computer Science from Purdue University and his Bachelors in Computer Science Engineering from The Ohio State University.
Laura Malahias has over 13 years of experience working in clinical research including assignments on all sides of the industry from study site, small and large CROs, to pharma. She is currently serving as Vice President, Clinical Operations at TARGET PharmaSolutions. Prior to her work at TARGET, Laura worked at Aerial BioPharma where she played an integral role in the development of ADX-N05 (Solriamfetol) which was sold to Jazz Pharmaceuticals.
Michael W. Fried, MD is Professor of Medicine and Director of Hepatology at the University of North Carolina at Chapel Hill. Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.
From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous phase I, II, and III clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for more than 15 years as principal investigator on multiple NIH cooperative clinical trials, including as current co-Chair of the Hepatitis B Research Network (NIDDK).
Dr. Fried is the recipient of an NIH career development award, which allows him to provide mentorship to junior investigators in hepatitis research. Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network of investigators to study the real-world experience with therapies for hepatitis C.
Dr. Fried is the primary author or co-author on over 140 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. His manuscript on therapy of HCV, published in 2002, established the standard of care for this disease for more than a decade and was one of the most highly cited publications in the field of gastroenterology.
Dr. Fried was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators. Dr. Fried was recently elected to the Governing Board of the American Association for the Study of Liver Diseases (AASLD) and will assume the role of President of AASLD in 2019.
Melissa is currently serving as Director of Human Resources at TARGET PharmaSolutions. Melissa Mulauski has over 18 years of human resources experience in employee relations, training, policy development, compensation, and recruiting.
Melissa spent 6 years working at Quintiles in their Human Resources department and another 3 years heading the Human Resources department at Peopleclick before joining Strategic HR Solutions as a Consultant.
Melissa is professionally certified as a Senior Professional in Human Resources (SPHR) and also as a SHRM Senior Certified Professional (SCP). She holds a Bachelor of Science degree in Labor and Industrial Relations with a Business minor from The Pennsylvania State University.
Matt Casbon is currently serving as Chief Business Officer for TARGET PharmaSolutions.
Prior to joining TARGET, Matt was Senior Vice President of Global Strategic Marketing at Circassia where he was responsible for global marketing, research sales and training.
Prior to Circassia, Matt worked as the Vice President of Marketing at KemPharm. Matt also previously worked at Chimerix, Salix Pharmaceuticals, Abbott Laboratories, and Solvay Pharmaceuticals in various roles of increasing responsibility.
He brings over 25 years of sales and marketing experience, including business development evaluations, product launches, pre-commercial strategy planning and sales force operations.
Matt received his BA from the West Chester University.
Richard joined TARGET PharmaSolutions in 2018 after seven years in the JMP Life Sciences division at SAS Institute, where he developed software to assess safety and data integrity in clinical trials utilizing CDISC standards. Prior to SAS, he spent eight years in the pharmaceutical industry, where he designed and analyzed clinical trials in diverse therapeutic areas including infectious disease, oncology, and ophthalmology, and participated in US and European drug submissions and FDA advisory committee hearings. Richard is the 2019 Chair of the Biopharmaceutical Section of the American Statistical Association, host of the Biopharmaceutical Section Statistics Podcast, and Associate Editor for the DIA journal Therapeutic Innovation & Regulatory Science. His research interests include data visualization, the analysis of pre- and post-market adverse events, subgroup identification for patients with enhanced treatment response, and the assessment of data integrity in clinical trials, and he participates in scientific working groups for safety and real-world evidence. Richard is the author of Risk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP and SAS, the co-editor of Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods, and a contributor to six other books on statistical topics in clinical trials and clinical research. He holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, where he serves as Adjunct Assistant Professor of Biostatistics.
Jen Woods is currently serving as Controller for TARGET PharmaSolutions.
Jen Woods has over 15 years of experience in the accounting and finance industry serving a variety of sectors, including life sciences, telecommunications, and banking. Before joining TARGET, Jen held various positions at Ernst & Young, LLP, the American Institute of CPAs, and Wachovia Bank. Most recently, she served in accounting and finance roles for private companies and non-profits. Jen is a client-focused, team player with strong communication skills and a proven track record of managing assignments and directing teams of professionals to produce results.
Mike McKelvey, Ph.D., has nearly three decades of experience building successful global organizations in the pharmaceutical services, healthcare IT, life sciences, technology and global core laboratory industries. Currently he is serving as Interim CEO of TARGET PharmaSolutions.
Prior to joining TARGET, Mike was President of Syneos Health Clinical Solutions, a global provider of comprehensive drug development services to the biopharmaceutical industry. A results-oriented, hands-on leader, he oversaw an organization of over 14,000 professionals with deep therapeutic capabilities in Phase I-III services, FSP services, Real World and Late Stage services, and Early Stage clinics and laboratories. Mike retired from Syneos in February 2019.
Eric Edell is Co-Founder and Co-Managing Partner of 22C Capital, a private equity firm committed to delivering capital and critical resources to companies operating at the intersection of technology enablement and data analytics adoption. The Firm has a dedicated focus on the healthcare services, business services, and financial services sectors. 22C's operational and technology resources, including its affiliated data science organization strive to deliver practical, real-world support to help convert these businesses' challenges into opportunities and unlock their full potential.
Mr. Edell received his B.A. in Neuroscience, summa cum laude, from the University of Pennsylvania, where he was a member of Phi Beta Kappa. He lives in New York City with his wife, Deborah, and their three children.
Ryan Harris, MD brings to Norwest Venture Partners more than twenty-five years of healthcare experience and fifteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, medical devices. Ryan’s current investments include Blue Cloud, Onsite Dental, and Rivermend Health. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare services, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture.
At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, Proteus Biomedical and Qualicaps.
At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle in 2002, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies.
Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics.
Mike McKelvey, Ph.D., leads Syneos Health Clinical Solutions, a global provider of comprehensive drug development services to the biopharmaceutical industry. Mike brings to his role nearly three decades of experience building successful global organizations in the pharmaceutical services, healthcare IT, life sciences, technology and global core laboratory industries. A results-oriented, hands-on leader, he oversees an organization of 14,000 professionals with deep therapeutic capabilities in Phase I-III services, FSP services, Real World and Late Stage services, and Early Stage clinics and laboratories.
As President of Clinical Solutions, Mike builds dynamic teams that help clients exceed their development and financial goals.
Before joining Syneos Health, he served as Executive Vice President and Chief Operating Officer at Aptiv Solutions, a global clinical development services company focused on adaptive clinical trial design. Aptiv Solutions was acquired by ICON in 2014. Prior to Aptiv Solutions, he was President and CEO and a board member of eResearch Technology, Inc. (ERT), a multiproduct provider of clinical research services. Prior to ERT, Dr. McKelvey led PAREXEL's Phase II-IV clinical operations for the Americas, as well as their global data management and global biostatistics groups.
Throughout his career, Mike has developed a reputation for combining high-level strategic expertise with flawless execution.
Mr. McKelvey holds a Ph.D. and M.A. in Business Economics from the Wharton School at the University of Pennsylvania and an A.B. degree in Economics from Williams College.
Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. Currently she is serving as Board Chair and is the Co-Founder of TARGET PharmaSolutions.
She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.
Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.
Paul Sekhri has over 30 years of experience in the Life Sciences Industry. In February 2015 he joined Lycera as President and CEO. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Chief Strategy Officer and Group Executive Vice President, Global Business Development for Teva Pharmaceutical Industries, Ltd. Prior to joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
From 1999-2002 Mr. Sekhri worked for Novartis AG, as Senior Vice President and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development - a department he established to ensure the differential competitive advantage of Novartis' pipeline.
Mr. Sekhri has been a Director on more than 24 private and public company Boards and is currently a member of the Board of Directors of Ipsen, S.A., Veeva Systems Inc., and Alpine Immune Sciences Inc. Mr. Sekhri is also the Chairman of the Board of Compugen Ltd., Pharming N.V., Petra Pharma Inc., and Topas Therapeutics GmbH.
Additionally, he serves on several non-profit Boards including the TB Alliance, The English Concert in America (TECA), The Knights, and most recently he joined the Board of the Metropolitan Opera. Mr. Sekhri also served as a Member of the Board of Trustees of Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.